Overview

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer

Phase:

Phase 1

Details

Lead Sponsor:

Kathy Miller

Collaborators:

Astex Pharmaceuticals, Inc.
Pfizer
Van Andel Institute Stand Up to Cancer Team

Treatments:

Hormones
Talazoparib